Biotech's first busy week of the new year came to an end yesterday on a down note, as Cadence Pharma (CADX) announced that its IV pain drug failed to meet its main Phase III trial goal. The announcement sent shares down more than 60%. For more information read here.
I'll stay busy next week bringing you more information from the sector as earnings season gets underway. First up is Genentech (DNA) Monday after the bell. Stay tuned.
January 12, 2008
Posted by Sizz at 10:36 PM